What is Engitix?
Founded in 2016 and headquartered in London, Engitix operates at the intersection of advanced biology and therapeutic innovation. The company has distinguished itself through the development of a sophisticated platform designed to identify novel drug targets within the human extracellular matrix. By focusing on complex disease areas such as fibrosis and solid tumors, Engitix has established a robust portfolio of programs that address significant unmet medical needs. Its unique approach to ECM-based discovery has already yielded two major strategic partnerships, positioning the firm as a high-value player in the biopharmaceutical landscape. The company's ability to translate complex biological insights into actionable drug development programs remains its core competitive advantage in a crowded therapeutic market.
How much funding has Engitix raised?
Engitix has raised a total of $85.2M across 2 funding rounds:
Series A
$60.2M
Series A
$25M
Series A (2022): $60.2M with participation from Dompé farmaceutici S.P.A and Netherton Investments
Series A (2026): $25M, investors not publicly disclosed
Key Investors in Engitix
Dompé farmaceutici S.P.A
A global biopharmaceutical company focused on research and development of innovative therapeutic solutions for rare and orphan diseases.
Netherton Investments
A private investment firm providing strategic capital to high-growth companies within the life sciences and technology sectors.
Undisclosed Investor
An undisclosed institutional backer participating in the latest funding round to support the company's long-term growth objectives.
What's next for Engitix?
With the recent injection of capital, Engitix is well-positioned to accelerate its transition from a discovery-focused entity to a clinical-stage powerhouse. The strategic roadmap likely involves the expansion of its internal R&D capabilities and the potential for further collaborative ventures to validate its ECM platform across broader therapeutic indications. As the company navigates the complexities of drug development, the focus will remain on de-risking its pipeline and achieving key milestones in fibrosis and oncology. Investors and industry observers will be closely monitoring the firm's progress as it leverages this latest financing to solidify its market position and advance its lead candidates toward clinical trials, ultimately aiming to deliver transformative treatments for patients suffering from chronic and life-threatening conditions.
See full Engitix company page
